A Study of Ta-NPs Plus Radiotherapy for Locally Recurrent Retroperitoneal Sarcoma

NCT07578506 | Not Yet Recruiting Phase 1 DMC

• 1 other identifier: HX 2026-937
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective, single-arm, open-label phase I study evaluates the safety and tolerability of intratumoral injection of tantalum nanoparticles (Ta-NPs) followed by radiotherapy in patients with locally recurrent retroperitoneal soft tissue sarcoma. Using a standard 3+3 dose-escalation design, three dose levels of Ta-NPs (injection volumes of 2%, 5%, and 10% of tumor volume, all at 30 mg/mL) are tested in sequential cohorts to identify dose-limiting toxicities.

Conditions

Locally Recurrent Retroperitoneal Soft Tissue Sarcoma

Keywords

Retroperitoneal Soft Tissue Sarcoma; Radiotherapy; Radiosensitizer; Nanomaterials

Outcome Measures

Primary Outcomes (1)

• Incidence of Dose-Limiting Toxicity (DLT)

  DLT is defined as any adverse event occurring during the DLT observation period (from the first intratumoral injection of Ta-NPs through Day 28 post-injection) that is judged by the investigator to be at least possibly related to Ta-NPs and meets prespecified DLT criteria.

  From day of Ta-NPs injection through day 28 post-injection

Secondary Outcomes (7)

• Incidence of Adverse Events

  From signing of informed consent through 90 days after last dose

• Pharmacokinetics (PK) of Ta-NPs

  Blood: Day 0 (pre-injection, 0 hour), and at 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 24 hours, Day 4, Day 8, Day 15, Day 28; Urine: Collected in intervals: 0-6 hours, 6-12 hours, 12-24 hours (Day 1), Day 2, Day 8, Day 15

• Objective Response Rate (ORR)

  Assessed at Week 3 (±2 days) after start of treatment, at treatment completion, and at Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, and Month 24 post-treatment initiation.

• Local Control Rate at 6 Months

  6 months post injection

• Progression-Free Survival (PFS)

  From injection until disease progression or death (up to approximately 36 months)

Other Outcomes (2)

• Changes in Tumor Immune Microenvironment

  Baseline (pre-treatment) and post-treatment (at time of salvage surgery or biopsy if clinically indicated)

• Changes in Peripheral Blood Immune Profile

  Baseline (pre-injection), Day 8, Day 15, Day 29, and at treatment completion

Study Arms (3)

Arm 1: Low-Dose Ta-NPs (2% Tumor Volume) Plus Radiotherapy

EXPERIMENTAL

Participants in this arm receive a single intratumoral injection of Ta-NPs at a concentration of 30 mg/mL, with the injection volume calculated as 2% of the baseline tumor volume . Injection is performed under imaging guidance (ultrasound or CT) prior to radiotherapy. Radiotherapy starts 24 hours after injection. Dose-limiting toxicity (DLT) is monitored during the first 28 days after Ta-NPs injection.

Biological: Ta-NPs (2% Tumor Volume); Radiation: Radiotherapy

Arm 2: Medium-Dose Ta-NPs (5% Tumor Volume) Plus Radiotherapy

EXPERIMENTAL

Participants in this arm receive a single intratumoral injection of Ta-NPs at a concentration of 30 mg/mL, with the injection volume calculated as 5% of the baseline tumor volume . Injection is performed under imaging guidance (ultrasound or CT) prior to radiotherapy. Radiotherapy starts 24 hours after injection. Dose-limiting toxicity (DLT) is monitored during the first 28 days after Ta-NPs injection.

Biological: Ta-NPs (5% Tumor Volume); Radiation: Radiotherapy

Arm 3: High-Dose Ta-NPs (10% Tumor Volume) Plus Radiotherapy

EXPERIMENTAL

Participants in this arm receive a single intratumoral injection of Ta-NPs at a concentration of 30 mg/mL, with the injection volume calculated as 10% of the baseline tumor volume . Injection is performed under imaging guidance (ultrasound or CT) prior to radiotherapy. Radiotherapy starts 24 hours after injection. Dose-limiting toxicity (DLT) is monitored during the first 28 days after Ta-NPs injection.

Biological: Ta-NPs (10% Tumor Volume); Radiation: Radiotherapy

Interventions

Ta-NPs (2% Tumor Volume) BIOLOGICAL

Ta-NPs at a concentration of 30 mg/mL administered via intratumoral injection at a volume equal to 2% of the baseline tumor volume (calculated as length × width × height). Injection is performed under imaging guidance (ultrasound/CT) prior to radiotherapy.

Arm 1: Low-Dose Ta-NPs (2% Tumor Volume) Plus Radiotherapy

Radiotherapy RADIATION

External beam radiotherapy delivered using a medical linear accelerator (energy ≥6 MV X-ray) with image-guided radiotherapy (IGRT). Techniques include intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT). Total dose follows NCCN/CSCO guidelines for soft tissue sarcoma. Fractionation: conventional fractionation (1.8-2.0 Gy per fraction, once daily, 5 days per week).

Arm 1: Low-Dose Ta-NPs (2% Tumor Volume) Plus Radiotherapy; Arm 2: Medium-Dose Ta-NPs (5% Tumor Volume) Plus Radiotherapy; Arm 3: High-Dose Ta-NPs (10% Tumor Volume) Plus Radiotherapy

Ta-NPs (5% Tumor Volume) BIOLOGICAL

Ta-NPs at a concentration of 30 mg/mL administered via intratumoral injection at a volume equal to 5% of the baseline tumor volume (calculated as length × width × height). Injection is performed under imaging guidance (ultrasound/CT) prior to radiotherapy.

Arm 2: Medium-Dose Ta-NPs (5% Tumor Volume) Plus Radiotherapy

Ta-NPs (10% Tumor Volume) BIOLOGICAL

Ta-NPs at a concentration of 30 mg/mL administered via intratumoral injection at a volume equal to 10% of the baseline tumor volume (calculated as length × width × height). Injection is performed under imaging guidance (ultrasound/CT) prior to radiotherapy.

Arm 3: High-Dose Ta-NPs (10% Tumor Volume) Plus Radiotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years, male or female.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Histopathologically confirmed diagnosis of dedifferentiated liposarcoma (DD-LPS) or leiomyosarcoma (LMS) with local or regional recurrence after prior standard treatment with curative intent. Prior treatment must include:
• a) Curative/radical or extended resection of the primary or first recurrent lesion. b) Possible prior treatments (if received) must be completed at least 4 weeks before enrollment, including: radiotherapy (external beam radiotherapy to the abdominopelvic region; detailed radiotherapy plan and DVH must be available to assess normal organ doses), chemotherapy (anthracycline- and/or ifosfamide-based systemic chemotherapy), or targeted therapy (e.g., anlotinib). c) All acute adverse events from prior treatments must have resolved to normal or Grade 1 per CTCAE.
• At least one lesion suitable for intratumoral injection (either directly or under imaging guidance) and radiotherapy, with a volume ≤3000 cm³ (tumor volume = length × width × height measured by CT/MRI), and measurable by imaging.
• Adequate hematologic and organ function within 7 days before first dose, meeting the following laboratory criteria:
• Hematology (without G-CSF within 14 days): Absolute neutrophil count (ANC) ≥1.5×10\^9/L; (without platelet transfusion within 14 days): Platelet count (PLT) ≥90×10\^9/L; (without red blood cell transfusion or erythropoietin within 14 days): Hemoglobin (Hb) ≥90 g/L.
• Renal function: Serum creatinine (Cr) ≤1.5×upper limit of normal (ULN), or calculated creatinine clearance (Cockcroft-Gault) ≥50 mL/min (only required if baseline Cr \>1.5×ULN).
• Liver function: Total bilirubin (TBIL) ≤1.5×ULN (or ≤3.0×ULN for Gilbert's syndrome or liver metastases); AST, ALT, and alkaline phosphatase (ALP) ≤2.5×ULN; serum albumin ≥2.8 g/dL.
• Coagulation: International normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.5×ULN.
• Cardiac: Left ventricular ejection fraction (LVEF) ≥50%.
• Expected survival ≥6 months.
• Willing and able to provide written informed consent, good compliance, and able to complete follow-up.

You may not qualify if:

• Presence of distant metastasis (M1 stage) that is not suitable for local radiotherapy intervention.
• Active skin ulceration, infection, erosion, necrosis, bleeding at the injection site, or risk of hollow organ perforation.
• The target lesion(s) have received radiotherapy within the past 6 months.
• Known allergy or intolerance to the active ingredient or excipients of Ta-NPs or similar nanoparticles.
• Pregnant or breastfeeding women; subjects (or their partners) who plan to become pregnant or have unprotected sexual intercourse without appropriate contraceptive measures (e.g., condoms, intrauterine devices, or partner sterilization) from screening through 3 months after study completion.
• HIV-positive; HCV-positive; HBsAg-positive or HBcAb-positive with detectable HBV DNA (quantitative assay ≥500 IU/mL).
• Active pulmonary tuberculosis, or history of pulmonary tuberculosis that has not been controlled after treatment.
• Other severe, uncontrolled concomitant diseases that may affect protocol compliance or interfere with interpretation of results, including active opportunistic or progressive (severe) infection, uncontrolled diabetes mellitus, cardiovascular disease (New York Heart Association Class III or IV heart failure, second-degree or higher atrioventricular block, myocardial infarction within the past 6 months, unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc.), or pulmonary disease (interstitial pneumonia, obstructive lung disease, symptomatic bronchospasm history).
• Active central nervous system (CNS) metastases or leptomeningeal disease. Subjects with treated brain metastases may be eligible if there is no evidence of progression on MRI for at least 8 weeks after treatment and within 28 days before first dose, and if systemic corticosteroids (\>10 mg prednisone equivalent/day) are not required for at least 2 weeks before study drug administration.
• Major surgical procedure (excluding diagnostic surgery) within 4 weeks before start of treatment.
• History of psychoactive substance abuse without ability to abstain, or history of psychiatric disorders.
• History of other malignancies within the past 5 years, except those that have been clearly cured or are curable, such as basal cell or squamous cell skin cancer, superficial bladder cancer or prostate carcinoma in situ, cervical carcinoma in situ, or breast carcinoma in situ.
• Any other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that, in the investigator's opinion, may increase the risk associated with study participation or may interfere with the interpretation of study results.
• Any condition that is not in the best interest of the participant.

Sponsors & Collaborators

• West China Hospital: lead

Study Sites (1)

Sichuan University West China Hospital, Chengdu, Sichuan

Chengdu, Sichuan, 610041, China

Location

Related Publications (12)

• Bonvalot S, Rutkowski PL, Thariat J, Carrere S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baere T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Verges R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovee JVMG, Le Pechoux C, Papai Z. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8.

  PMID: 31296491 BACKGROUND

• Leite ETT, Munhoz RR, Camargo VP, Lima LGCA, Rebolledo DCS, Maistro CEB, Busnardo FF, Ferreira FO, Salvajoli JV, Carvalho HA. Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities. Radiother Oncol. 2021 Aug;161:222-229. doi: 10.1016/j.radonc.2021.06.027. Epub 2021 Jun 22.

  PMID: 34171452 BACKGROUND

• Rhomberg W, Hassenstein EO, Gefeller D. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1077-84. doi: 10.1016/s0360-3016(96)00433-6.

  PMID: 8985029 BACKGROUND

• Rhomberg W. The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane. Sarcoma. 2006;2006(1):87367. doi: 10.1155/SRCM/2006/87367.

  PMID: 17040092 BACKGROUND

• Khokhar MA, Akhtar M, Shah Gillani SFUH, Abdulsalaam R, Qamar S. Radiotherapy alone with concurrent chemoradiotherapy plus temozolamide in locally advanced soft tissue sarcoma at Mayo Hospital Lahore: A randomized controlled trial. J Pak Med Assoc. 2020 Apr;70(4):572-576. doi: 10.5455/JPMA.293442.

  PMID: 32296197 BACKGROUND

• Huang Z, Li N, Tang Y, Jin J, Liu W, Xu H, Yu F, Hao L, Zhang Q, Ding Y, Niu X. Neoadjuvant radiotherapy for soft tissue sarcoma in China: a preliminary result. Ann Transl Med. 2022 Apr;10(8):452. doi: 10.21037/atm-22-98.

  PMID: 35571451 BACKGROUND

• Hayes AJ, Nixon IF, Strauss DC, Seddon BM, Desai A, Benson C, Judson IR, Dangoor A. UK guidelines for the management of soft tissue sarcomas. Br J Cancer. 2025 Jan;132(1):11-31. doi: 10.1038/s41416-024-02674-y. Epub 2024 May 11.

  PMID: 38734790 BACKGROUND

• Hogg HD, Manas DM, Lee D, Dildey P, Scott J, Lunec J, French JJ. Surgical outcome and patterns of recurrence for retroperitoneal sarcoma at a single centre. Ann R Coll Surg Engl. 2016 Mar;98(3):192-7. doi: 10.1308/rcsann.2016.0057. Epub 2016 Feb 14.

  PMID: 26876538 BACKGROUND

• Schwartz PB, Vande Walle K, Winslow ER, Ethun CG, Tran TB, Poultsides G, Tseng J, Roggin K, Grignol V, Howard JH, Krasnick BA, Fields RC, Mogal H, Clarke CN, Senehi R, Votanopoulos K, Cardona K, Abbott DE. Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A Modern 16-Year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC). Sarcoma. 2019 Jun 2;2019:5395131. doi: 10.1155/2019/5395131. eCollection 2019.

  PMID: 31281208 BACKGROUND

• Buja A, Rugge M, Barillaro M, Miatton A, Tropea S, Cozzolino C, Zorzi M, Vecchiato A, Del Fiore P, Brunello A, Baldo V, Rossi CR, Mocellin S. Epidemiology, pathological characteristics and survival of retroperitoneal soft-tissue sarcomas compared with non-retroperitoneal soft tissue sarcomas. Oncol Lett. 2023 May 26;26(1):301. doi: 10.3892/ol.2023.13887. eCollection 2023 Jul.

  PMID: 37323817 BACKGROUND

• Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, Ness KK, Casanova M, Spunt SL. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011 Dec 1;57(6):943-9. doi: 10.1002/pbc.23252. Epub 2011 Jul 25.

  PMID: 21793180 BACKGROUND

• Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006 Apr 1;106(7):1610-6. doi: 10.1002/cncr.21761.

  PMID: 16518798 BACKGROUND

MeSH Terms

Interventions

Tumor Burden; Radiotherapy

Intervention Hierarchy (Ancestors)

Body Weights and Measures; Anthropometry; Investigative Techniques; Therapeutics

Central Study Contacts

Xingchen Peng, MD, PhD

CONTACT

+8618980606753; pxx2014@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 27, 2026
• First Posted: May 11, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): May 1, 2027
• Last Updated: May 11, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)